Paclitaxel (Taxol) is an anticancer drug that induces mitotic arrest via microtubule hyperstabilization but causes side effects due to its hydrophobicity and cellular promiscuity. The targeted cytotoxicity of hydrophilic paclitaxel-conjugated polyamidoamine (PAMAM) dendrimers has been demonstrated in cultured cancer cells. Mechanisms of action responsible for this cytotoxicity are unknown, that...

•First case report of successfully treating severe paclitaxel and docetaxel hypersensitivity reaction with nab-paclitaxel•We demonstrated that nab-paclitaxel is a safe taxane chemotherapy treatment option for patients who could not tolerate paclitaxel or docetaxel.

Tujuan: Mengetahui perbandingan respon terapi dan toksisitas regimen kemoterapi kombinasi Paclitaxel Carboplatin Ifosfamide dengan pada kanker serviks stadium IIB. Metode: Sebanyak 30 pasien yang baru terdiagnosis IIB dibagi menjadi dua kelompok yaitu Paclitaxel-Carboplatin-Ifosfamide (TIP) Paclitaxel-Carboplatin (TP). Volume tumor diukur sebelum sesudah tiga siklus kemoterapi. Hasil:Tingkat pe...

Non-small-cell lung cancer (NSCLC) is one of the most leading causes of cancer-related deaths worldwide. Paclitaxel based combination therapies have long been used as a standard treatment in aggressive NSCLCs. But paclitaxel resistance has emerged as a major clinical problem in combating non-small-cell lung cancer and autophagy is one of the important mechanisms involved in this phenomenon. In ...

Nanoparticle albumin-bound (nab)-paclitaxel appears to exhibit better response rates in patients with metastatic urothelial cancer of the bladder whom are pretreated with nab-paclitaxel compared with conventional paclitaxel. Paclitaxel may induce multidrug resistance in patients with cancer, while the mechanisms of resistance against paclitaxel are manifold. These include reduced function of pr...

PURPOSE Docosahexaenoic acid (DHA)-paclitaxel, a novel conjugate formed by covalently linking the natural fatty acid DHA to paclitaxel, was designed as a prodrug targeting intratumoral activation. This Phase I trial examined its toxicity and pharmacokinetics (PKs). EXPERIMENTAL DESIGN Patients with advanced refractory solid tumors received a 2-h i.v. infusion of DHA-paclitaxel every 3 weeks. ...

Background Real-world analyses of treatments for patients with metastatic breast cancer are limited. We evaluated the comparative effectiveness of nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer using data from an electronic medical record database from community practices across the USA. Methods We performed a retrospective cohort study using fully de-identified data ...

BACKGROUND Paclitaxel can inhibit vascular smooth muscle proliferation in vitro, and early studies suggest that paclitaxel may be useful in preventing restenosis. Early and late intimal growth and local vascular pathological changes associated with paclitaxel delivered via stents have not been fully explored. METHODS AND RESULTS Localized drug delivery was accomplished with balloon-expandable...

Chemoresistance is one of the main factors treatment failure cervical cancer (CC). Here, we intended to discover role and mechanism miR-509-5p in paclitaxel chemoresistance CC cells. RT-PCR was conducted verify miR-509-3p expression. HCC94 C-33A paclitaxel-resistant cell models were constructed. Additionally, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay flow cytometr...

Abstract Background Paclitaxel-induced peripheral neuropathy (PIPN) is a dose-limiting axonal polyneuropathy. Nerve conduction studies (NCS) are unique for the assessment of impairment in PIPN. Neurofilaments (NFs), constituent neuronal cytoskeleton, emerging as damage biomarker. To date, association between changes NCS and NfL quantification across paclitaxel treatment breast cancer patients h...